Antibody conjugates comprising toll-like receptor agonist
作者： Shailaja Kasibhatla , Timothy Z. Hoffman , Tom Yao-Hsiang Wu , Alex Cortez , Tetsuo Uno
DOI:
关键词: Antibody 、 Toll-like receptor 、 Cancer research 、 Conjugate 、 Cancer 、 Agonist 、 Receptor 、 Chemistry
摘要: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such for treatment cancer. In some embodiments, comprise anti-HER2 antibodies.
lens.org参考文章(105)
Pharmaceutical Dosage Forms : Parenteral Medications Routledge. ,(2018) , 10.1201/9780203743676
Myra L. Weiner, Lois A. Kotkoskie, Excipient Toxicity and Safety ,(1999)
J. F. W. McOmie, Protective Groups in Organic Chemistry ,(2012)
Jean-François Bach, Monoclonal antibodies and peptide therapy in autoimmune diseases M. Dekker. ,(1993)
Solomon Langermann, Simultaneous inhibition of pd-l1/pd-l2 ,(2010)
Shiang C. Gwee, Ye Shen, Jun Liu, James Andya, Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody ,(2012)
Deborah Luxenberg, Viia Valge-Archer, Frances K. Bennett, Clive R. Wood, Caroline Russell, John Andrews, Jason Jussif, Laura L. Carter, Mary Collins, Beatriz M. Carreno, Methods of upmodulating adaptive immune response using anti-PD-1 antibodies ,(2003)
Elvin A. Kabat, Sequences of proteins of immunological interest National Institutes of Health. ,(1991)
Herbert A. Lieberman, Leon Lachman, Pharmaceutical dosage forms : tablets Marcel Dekker. ,(1980)
Paul A. Motchnik, Reed J. Harris, Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof ,(2009)